Skip to main content
SpringerLink
Log in

Benigne und maligne Erkrankungen der Brust

  • Chapter
  • First Online:
Klinische Endokrinologie für Frauenärzte

  • 201 Accesses

Zusammenfassung

Das Wachstum und die Differenzierung der Brustdrüse in Adoleszens, Schwangerschaft und Stillzeit sind abhängig vom Hormonhaushalt des Körpers. Die Entwicklung vieler benigner und maligner Erkrankungen der Brust ist ebenfalls hormonabhängig. Insbesondere Estradiol und Progesteron, aber auch andere Hormone wie Prolaktin, Somatotropin, Kortisol und Thyroxin spielen hier eine Rolle. Auch in der Behandlung von Erkrankungen der Mamma werden häufig Medikamente verwendet, die in das endokrine System eingreifen. Dieses Kapitel beschreibt die benignen und malignen Erkrankungen der Brust sowie deren Vorstufen, einschließlich der möglichen Therapieoptionen. Das besondere Augenmerk liegt hierbei auf dem Einfluss von endogenen und exogenen Hormonen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, Clavel-Chapelon F, Fabre A, Hémon B, Rinaldi S, Chajes V, Slimani N, Allen NE, Reeves GK, Bingham S, Khaw KT, Olsen A, Tjønneland A, Rodriguez L, Sánchez MJ, Etxezarreta PA, Ardanaz E, Tormo MJ, Peeters PH, van Gils CH, Steffen A, Schulz M, Chang-Claude J, Kaaks R, Tumino R, Gallo V, Norat T, Riboli E, Panico S, Masala G, González CA, Berrino F (2011) Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 128:144–156

    Article  CAS  PubMed  Google Scholar 

  • Beaber EF, Malone KE, Tang MT, Barlow WE, Porter PL, Daling JR, Li CI (2014) Oral contraceptives and breast cancer risk overall and by molecular subtype among young women. Cancer Epidemiol Biomark Prev 23:755–764

    Article  CAS  Google Scholar 

  • Bérubé S, Lemieux J, Moore L, Maunsell E, Brisson J (2014) Smoking at time of diagnosis and breast cancer-specific survival: new findings and systematic review with meta-analysis. Breast Cancer Res 16:R42

    Article  PubMed  PubMed Central  Google Scholar 

  • Chlebowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, Lane DS, Johnson KC, Wactawski-Wende J, Chen C, Qi L, Yasmeen S, Newcomb PA, Prentice RL (2013) Estrogen plus progestin and breast cancer incidence and mortality in the Women’s Health Initiative Observational Study. J Natl Cancer Inst 105:526–535

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Collaborative Group on Hormonal Factors in Breast Cancer (2019) Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 394(10204):1159–1168

    Article  PubMed Central  Google Scholar 

  • Cordina-Duverger E, Truong T, Anger A, Sanchez M, Arveux P, Kerbrat P, Guénel P (2013) Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLoS One 8:e78016

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R (2013) Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Donders G, Neven P, Moegele M, Lintermans A, Bellen G, Prasauskas V, Grob P, Ortmann O, Buchholz S (2014) Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat 145:371–379

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dyrstad SW, Yan Y, Fowler AM, Colditz GA (2015) Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast Cancer Res Treat 149:569–575

    Article  CAS  PubMed  Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784

    Article  Google Scholar 

  • Empfehlungen gynäkologische Onkologie Kommission Mamma (AGO): Läsionen mit unsicherem biologischen Potenzial (B3), Stand 01.03.2021; Adjuvante endokrine Therapie in prä- und postmenopausalen Patientinnen, Stand 02.03.2021

    Google Scholar 

  • Fahlén M, Fornander T, Johansson H, Johansson U, Rutqvist LE, Wilking N, von Schoultz E (2013) Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer 49:52–59

    Article  PubMed  Google Scholar 

  • Farshid G, Buckley E (2019) Meta-analysis of upgrade rates in 3163 radial scars excised after needle core biopsy diagnosis. Breast Cancer Res Treat 174:165–177

    Article  PubMed  Google Scholar 

  • Fournier A, Berrino F, Clavel-Chapelon F (2008) Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107:103–111

    Article  CAS  PubMed  Google Scholar 

  • Gallagher EJ, LeRoith D (2010) The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 21:610–618

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262–1271

    Article  CAS  PubMed  Google Scholar 

  • Greil H (2007) Frühentwickler – Spätentwickler: Sexuelle Reifungszeichen als Marker für das biologische Alter. In korasion, Nr. 1, Februar 2007; online abrufbar bei Arbeitsgemeinschaft Kinder- und Jugendgynäkologie e. V. (AG), Stand Januar 2022

    Google Scholar 

  • Hartmann LC, Degnim AC, Santen RJ, Dupont WD, Ghosh K (2015) Atypical hyperplasia of the breast – risk assessment and management options. N Engl J Med 372:78–89

    Article  PubMed  PubMed Central  Google Scholar 

  • Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, Jassem J, Dobaczewska D, Fjosne HE, Peralta O, Arriagada R, Holmqvist M, Maenpaa J, HABITS Study Group (2008) Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 100:475–482

    Article  CAS  PubMed  Google Scholar 

  • Jernström H, Loman N, Johannsson OT, Borg A, Olsson H (2005) Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing. Eur J Cancer 41:2312–2320

    Article  PubMed  Google Scholar 

  • Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, Cortés J, Huober J, Wardley A, Tolaney SM, Cicin I, Smith IC, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O’Shaughnessy J, Rastogi P, monarchE Committee Members and Investigators (2020) Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol 38:3987–3998

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jung MM, Colditz GA, Collins LC, Schnitt SJ, Connolly JL, Tamimi RM (2011) Lifetime physical activity and the incidence of proliferative benign breast disease. Cancer Causes Control 22:1297–1305

    Article  PubMed  PubMed Central  Google Scholar 

  • Kang C, LeRoith D, Gallagher EJ (2018) Diabetes, obesity and breast cancer. Endocrinology 159:3801–3812

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van Os S, Beckmann MW, LIBERATE Study Group (2009) Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 10:135–146

    Article  CAS  PubMed  Google Scholar 

  • Key T, Appleby P, Barnes I, Reeves G, Endogenous Hormones and Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606–616

    Article  CAS  PubMed  Google Scholar 

  • Kotsopoulos J, Narod SA (2012) Androgens and breast cancer. Steroids 77:1–9

    Article  CAS  PubMed  Google Scholar 

  • Kotsopoulos J, Huzarski T, Gronwald J, Singer CF, Moller P, Lynch HT, Armel S, Karlan B, Foulkes WD, Neuhausen SL, Senter L, Tung N, Weitzel JN, Eisen A, Metcalfe K, Eng C, Pal T, Evans G, Sun P, Lubinski J, Narod SA, Hereditary Breast Cancer Clinical Study Group (2016) Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 109:djw177

    PubMed  PubMed Central  Google Scholar 

  • LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, Howard BV, Lewis CE, Wactawski-Wende J (2011) WHI investigators. JAMA 305:1305–1314

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lamy PJ, Pujol P, Thezenas S, Kramar A, Rouanet P, Guilleux F, Grenier J (2002) Progesterone receptor quantification as a strong prognostic determinant in postmenopausal breast cancer women under tamoxifen therapy. Breast Cancer Res Treat 76:65–71

    Article  CAS  PubMed  Google Scholar 

  • Loibl S, Marmé F, Martin M, Untch M, Bonnefoi H, Kim SB, Bear H, McCarthy N, Melé Olivé M, Gelmon K, García-Sáenz J, Kelly CM, Reimer T, Toi M, Rugo HS, Denkert C, Gnant M, Makris A, Koehler M, Huang-Bartelett C, Lechuga Frean MJ, Colleoni M, Werutsky G, Seiler S, Burchardi N, Nekljudova V, von Minckwitz G (2021) Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-the penelope-B trial. J Clin Oncol 39:1518–1530

    Article  CAS  PubMed  Google Scholar 

  • Mamounas EP, Bandos H, Lembersky BC, Jeong JH, Geyer CE Jr, Rastogi P, Fehrenbacher L, Graham ML, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Seay TE, Wade JL 3rd, McCarron EC, Paik S, Swain SM, Wickerham DL, Wolmark N (2019) Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:88–99

    Article  CAS  PubMed  Google Scholar 

  • Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Chlebowski RT, Howard BV, Thomson CA, Margolis KL, Lewis CE, Stefanick ML, Jackson RD, Johnson KC, Martin LW, Shumaker SA, Espeland MA, Wactawski-Wende J, WHI Investigators (2017) Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women’s health initiative randomized trials. JAMA 318:927–938

    Article  PubMed  PubMed Central  Google Scholar 

  • Marchetti C, De Felice F, Boccia S, Sassu C, Di Donato V, Perniola G, Palaia I, Monti M, Muzii L, Tombolini V, Benedetti Panici P (2018) Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis. Crit Rev Oncol Hematol 132:111–115

    Article  CAS  PubMed  Google Scholar 

  • Mayer EL, Dueck AC, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerra M, Miller KD, Zdenkowski N, Winer EP, Pfeiler G, Goetz M, Ruiz-Borrego M, Anderson D, Nowecki Z, Loibl S, Moulder S, Ring A, Fitzal F, Traina T, Chan A, Rugo HS, Lemieux J, Henao F, Lyss A, Antolin Novoa S, Wolff AC, Vetter M, Egle D, Morris PG, Mamounas EP, Gil-Gil MJ, Prat A, Fohler H, Metzger Filho O, Schwarz M, DuFrane C, Fumagalli D, Theall KP, Lu DR, Bartlett CH, Koehler M, Fesl C, DeMichele A, Gnant M (2021) Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 22:212–222

    Article  CAS  PubMed  Google Scholar 

  • McCormack VA, dos Santos SI (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev 15:1159–1169

    Article  Google Scholar 

  • Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø (2017) Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med 377:2228–2239

    Article  PubMed  Google Scholar 

  • Prechtel K, Gehm O, Geiger G, Prechtel P (1994) The histology of mastopathy andcumulative ipsilateral breast cancer sequence. Pathologe 15:158–164

    Article  CAS  PubMed  Google Scholar 

  • Prentice RL, Manson JE, Langer RD et al (2009) Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 170(1):12–23

    Google Scholar 

  • Rageth CJ, O’Flynn EA, Comstock C, Kurtz C, Kubik R, Madjar H, Lepori D, Kampmann G, Mundinger A, Baege A, Decker T, Hosch S, Tausch C, Delaloye JF, Morris E, Varga Z (2016) First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast Cancer Res Treat 159:203–213

    Article  PubMed  PubMed Central  Google Scholar 

  • Rohan TE, Negassa A, Chlebowski RT, Lasser NL, McTiernan A, Schenken RS, Ginsberg M, Wassertheil-Smoller S, Page DL (2008) Estrogen plus progestin and risk of benign proliferative breast disease. Cancer Epidemiol Biomark Prev 17:2337–2343

    Article  CAS  Google Scholar 

  • Russo J, Mailo D, Hu YF, Balogh G, Sheriff F, Russo ICH (2005) Breast differentiation and its implication in cancer prevention. Clin Cancer Res 11:931s–936s

    Article  CAS  PubMed  Google Scholar 

  • S3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms: AWMF-Registernummer 032-045OL; 2021

    Google Scholar 

  • S3-Leitlinie Peri- und Postmenopause – Diagnostik und Interventionen: AWMF-Registernummer 015-062; 2020

    Google Scholar 

  • Schünke M, Schulte E, Schumacher U, Voll M, Wesker K (2007) Prometheus LernAtlas der Anatomie: Allgemeine Anatomie und Bewegungssystem, 2. Aufl. Thieme, Stuttgart

    Google Scholar 

  • Scoccianti C, Lauby-Secretan B, Bello PY, Chajes V, Romieu I (2014) Female breast cancer and alcohol consumption: a review of the literature. Am J Prev Med 46:S16–S25

    Article  PubMed  Google Scholar 

  • Singh DD, Dharanipragada K, D S, Manikandan S (2020) Oral versus topical tamoxifen in cyclical mastalgia-A randomized controlled trial. Breast J 26(4):743–747

    Google Scholar 

  • Slamon DJ, Stroyakovskiy D, Yardley DA, Huang C-S, Fasching PA, Crown J et al (2023) Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial. J Clin Oncol 41(17_suppl): LBA500-LBA500

    Google Scholar 

  • Staley H, McCallum I, Bruce J (2014) Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis. Breast 23:546–551

    Article  CAS  PubMed  Google Scholar 

  • Thomas PS (2018) Diagnosis and management of high-risk breast lesions. J Natl Compr Cancer Netw 16:1391–1396

    Article  Google Scholar 

  • Wen X, Cheng W (2013) Nonmalignant breast papillary lesions at core-needle biopsy: a meta-analysis of underestimation and influencing factors. Ann Surg Oncol 20:94–101

    Article  PubMed  Google Scholar 

  • Wolf A, Esser Mittag J (2002) Kinder- und Jugendgynäkologie: Atlas und Leitfaden für die Praxis, 2. Aufl. Schattauer, Stuttgart

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsfrauenklinik Regensburg, Regensburg, Deutschland

    D. Huber & O. Ortmann

Authors
  1. D. Huber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Ortmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Huber .

Editor information

Editors and Affiliations

  1. Abt. Gynäkologische Endokrinologie und Fertilitätsstörungen, Universitäts-Frauenklinik Heidelberg, Heidelberg, Deutschland

    Thomas Strowitzki

  2. Universitätsfrauenklinik Regensburg, Regensburg, Deutschland

    Olaf Ortmann

Rights and permissions

Reprints and permissions

Copyright information

© 2024 Der/die Autor(en), exklusiv lizenziert an Springer-Verlag GmbH, DE, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Huber, D., Ortmann, O. (2024). Benigne und maligne Erkrankungen der Brust. In: Strowitzki, T., Ortmann, O. (eds) Klinische Endokrinologie für Frauenärzte. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-65517-7_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-65517-7_13

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-65516-0

  • Online ISBN: 978-3-662-65517-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation